Business Description
PharmaResearch Co Ltd
ISIN : KR7214450009
Compare
Compare
Traded in other countries / regions
214450.Korea IPO Date
2015-07-24Description
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.78 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.26 | |||||
| Interest Coverage | 137.08 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 19.04 | |||||
| Beneish M-Score | -2.33 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 30.8 | |||||
| 3-Year EBITDA Growth Rate | 29.5 | |||||
| 3-Year EPS without NRI Growth Rate | 25.4 | |||||
| 3-Year Book Growth Rate | 18.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 27.33 | |||||
| Future 3-5Y Total Revenue Growth Rate | 24.03 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.1 | |||||
| 9-Day RSI | 71.8 | |||||
| 14-Day RSI | 67.93 | |||||
| 6-1 Month Momentum % | 29.17 | |||||
| 12-1 Month Momentum % | 80.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.01 | |||||
| Quick Ratio | 3.38 | |||||
| Cash Ratio | 2.57 | |||||
| Days Inventory | 204.51 | |||||
| Days Sales Outstanding | 37.83 | |||||
| Days Payable | 28.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.37 | |||||
| Dividend Payout Ratio | 0.11 | |||||
| 3-Year Dividend Growth Rate | 23.9 | |||||
| Forward Dividend Yield % | 0.37 | |||||
| 5-Year Yield-on-Cost % | 1.21 | |||||
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 1.17 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 70.98 | |||||
| Operating Margin % | 35.56 | |||||
| Net Margin % | 28 | |||||
| FCF Margin % | 29.33 | |||||
| ROE % | 19.46 | |||||
| ROA % | 15.35 | |||||
| ROIC % | 25.91 | |||||
| ROC (Joel Greenblatt) % | 61.9 | |||||
| ROCE % | 22.02 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 35.28 | |||||
| Forward PE Ratio | 21.77 | |||||
| PE Ratio without NRI | 32.11 | |||||
| Price-to-Owner-Earnings | 30.36 | |||||
| PEG Ratio | 0.86 | |||||
| PS Ratio | 9.69 | |||||
| PB Ratio | 5.41 | |||||
| Price-to-Tangible-Book | 5.78 | |||||
| Price-to-Free-Cash-Flow | 32.6 | |||||
| Price-to-Operating-Cash-Flow | 25.02 | |||||
| EV-to-EBIT | 23.28 | |||||
| EV-to-EBITDA | 20.86 | |||||
| EV-to-Revenue | 8.11 | |||||
| EV-to-FCF | 27.67 | |||||
| Price-to-Projected-FCF | 3.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.28 | |||||
| Price-to-Graham-Number | 2.87 | |||||
| Price-to-Net-Current-Asset-Value | 13.33 | |||||
| Price-to-Net-Cash | 32.2 | |||||
| Earnings Yield (Greenblatt) % | 4.3 | |||||
| FCF Yield % | 3.37 | |||||
| Forward Rate of Return (Yacktman) % | 21.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
PharmaResearch Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 316,996.823 | ||
| EPS (TTM) (â‚©) | 7554 | ||
| Beta | 0.56 | ||
| Volatility % | 49.14 | ||
| 14-Day RSI | 67.93 | ||
| 14-Day ATR (â‚©) | 14235.408576 | ||
| 20-Day SMA (â‚©) | 232775 | ||
| 12-1 Month Momentum % | 80.36 | ||
| 52-Week Range (â‚©) | 86800 - 270000 | ||
| Shares Outstanding (Mil) | 10.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PharmaResearch Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PharmaResearch Co Ltd Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
PharmaResearch Co Ltd Frequently Asked Questions
What is PharmaResearch Co Ltd(XKRX:214450)'s stock price today?
The current price of XKRX:214450 is â‚©266500.00. The 52 week high of XKRX:214450 is â‚©270000.00 and 52 week low is â‚©86800.00.
When is next earnings date of PharmaResearch Co Ltd(XKRX:214450)?
The next earnings date of PharmaResearch Co Ltd(XKRX:214450) is .
Does PharmaResearch Co Ltd(XKRX:214450) pay dividends? If so, how much?
The Dividend Yield %  of PharmaResearch Co Ltd(XKRX:214450) is 0.37% (As of Today), Highest Dividend Payout Ratio of PharmaResearch Co Ltd(XKRX:214450) was 0.27. The lowest was 0.11. And the median was 0.14. The  Forward Dividend Yield % of PharmaResearch Co Ltd(XKRX:214450) is 0.37%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers